E
Equinox Biologics develops next-generation Myeloid Cell Engagers (MCEs) for therapeutic use. This platform technology aims to induce tolerance in patients suffering from autoimmune diseases. The company focuses on achieving clinical remission through targeted modulation of myeloid cell function.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Equinox Biologics develops next-generation Myeloid Cell Engagers (MCEs) for therapeutic use. This platform technology aims to induce tolerance in patients suffering from autoimmune diseases. The company focuses on achieving clinical remission through targeted modulation of myeloid cell function.